The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Ellence     (7S,9R)-7-[(2S,4S,5R,6S)-4- amino-5-hydroxy...

Synonyms: Epirubitec, Farmorubicin, Farmorubicina, Pharmorubicin, IMI-28, ...
This record was replaced with 41867.
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of IMI 28

 

High impact information on IMI 28

 

Biological context of IMI 28

 

Anatomical context of IMI 28

  • The enhancement of P-L fusion under the action of FR and CR can most likely be explained by changes of the cytoskeleton state [10].
 

Associations of IMI 28 with other chemical compounds

  • Hypoxic upper abdominal chemotherapy was carried out using Mitomycin-C, 5-Fluorouracil, Leucovorin, and Farmorubicin, 10 days before surgery, and 20 days following surgery, in Group A (n=20) with or without in Group B (n=19) systemic chemotherapy; the remaining patients (Group C: n=19) had neither neo nor adjuvant treatment [11].
  • The offspring of Wistar rats obtained from parents, one of which received platinum-containing drug Platidiam (cisplatin) or anthracycline antibiotics Doxorubicin and Farmorubicin was characterized by low viability (embryonic death increased 4-30-fold compared to control) and congenital malformations [12].
  • Instillation of 50 mg epirubicin (Farmorubicin, Farmitalia Carlo Erba) diluted in 50 ml saline was followed by 80 mg of the Connaught strain bacillus Calmette-Guérin (ImmuCyst, Pasteur Mérieux) in 50 ml saline and the duration of instillation was 2 h for each drug [13].
 

Analytical, diagnostic and therapeutic context of IMI 28

  • Nearly 100% cytotoxicity, mutagenicity and antibacterial activity were eliminated and HPLC did not detect an EH molecule, in the case of electrolysis for 6 h [14].
  • After 15 days of immunostimulation bolus injection of chemotherapy was given including, lipiodol 10ml, urographin 2ml, mitomycin C 0.2mg/kg, carboplatin 1.5mg/kg, farmorubicin 1mg/kg, 5-fluorouracil 10mg/kg, and leukovorin 1.5mg/kg [15].

References

  1. Spin-labeled 1-alkyl-1-nitrosourea synergists of antitumor antibiotics. Gadjeva, V., Koldamova, R. Anticancer Drug Des. (2001) [Pubmed]
  2. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of L-TAE with Farmorubicin and L-TAE with adriamycin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Okamura, J., Kawai, S., Ogawa, M., Ohashi, Y., Tani, M., Inoue, J., Kawarada, Y., Kusano, M., Kubo, Y., Kuroda, C. Cancer Chemother. Pharmacol. (1992) [Pubmed]
  3. Diminished genotoxicity of mitomycin C and farmorubicin included in polybutylcyanoacrylate nanoparticles. Blagoeva, P.M., Balansky, R.M., Mircheva, T.J., Simeonova, M.I. Mutat. Res. (1992) [Pubmed]
  4. A case of primary cardiac lymphoma located in the pericardial effusion. Nakakuki, T., Masuoka, H., Ishikura, K., Seko, T., Koyabu, S., Tamai, T., Sugawa, M., Ito, M., Nakano, T. Heart and vessels. (2004) [Pubmed]
  5. Management of uterine Müllerian adenosarcoma with extrauterine metastatic deposits. Guidozzi, F., Smith, T., Koller, A.B., Reinecke, L. Gynecol. Oncol. (2000) [Pubmed]
  6. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. Lygidakis, N.J., Kosmidis, P., Ziras, N., Parissis, J., Kyparidou, E. J. Interferon Cytokine Res. (1995) [Pubmed]
  7. Efficacy of CO2-DSA in embolization. Teshima, Y., Iwasaki, N. Cancer Chemother. Pharmacol. (1994) [Pubmed]
  8. Resistance of multicellular aggregates to pharmorubicin observed in human hepatocarcinoma cells. Jianmin, Z., Hongfang, W., Meifu, F. Braz. J. Med. Biol. Res. (2002) [Pubmed]
  9. Effects of anthracyclines on reproductive function in rats. Borovskaya, T.G., Gol'dberg, E.D. Bull. Exp. Biol. Med. (2000) [Pubmed]
  10. Effects of some biologically active compounds on phagosome-lysosome fusion in peritoneal macrophages of mice. Mozhenok, T., Belyaeva, T., Bulychev, A., Kuznetsova, I., Leontieva, E., Faddejeva, M. Cell Biol. Int. (1998) [Pubmed]
  11. Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial. Lygidakis, N.J., Sgourakis, G., Aphinives, P. Hepatogastroenterology (1999) [Pubmed]
  12. Effects of antitumor drugs on offspring. Gol'dberg, E.D., Borovskaya, T.G., Poluektova, M.E. Bull. Exp. Biol. Med. (2000) [Pubmed]
  13. Trial with bacillus Calmette-Guérin and epirubicin combination in the prophylaxis of superficial bladder cancer. Erol, A., Ozgür, S., Basar, M., Cetin, S. Urologia internationalis. (1994) [Pubmed]
  14. Inactivation of antineoplastics in clinical wastewater by electrolysis. Hirose, J., Kondo, F., Nakano, T., Kobayashi, T., Hiro, N., Ando, Y., Takenaka, H., Sano, K. Chemosphere (2005) [Pubmed]
  15. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2). Abdel-Wahab, M., El-Shennawy, F., Agha, S., Ragab, E., Fathi, O., Sultan, A., Elghawalby, N., Ezzat, F. Hepatogastroenterology (1999) [Pubmed]
 
WikiGenes - Universities